FDA Roundtable: Strengthening the Supply Chain for Blood Manufacturing September 29, 2026

Meeting | Virtual

---

• Date: September 29, 2026
• Time: 9:00 a.m. - 4:00 p.m. ET

• Organized By: Center for Biologics Evaluation and Research (CBER)

Meeting Overview:

On September 29, 2026, the Food and Drug Administration’s, Center for Biologics Evaluation and Research, Office of Blood Research and Review is hosting a roundtable on strengthening the supply chain for the collection and manufacturing of Whole Blood and blood components for transfusion and further manufacturing, including Source Plasma.
The purpose of the roundtable is to identify supply chain challenges and potential solutions to prevent shortages of supplies and equipment used in blood manufacturing to help ensure a safe and adequate blood supply in the United States. During this one-day meeting, FDA and other key stakeholders, including representatives from the blood collection industry, supply chain manufacturers, and federal agencies in the Department of Health and Human Services will discuss current challenges and offer strategies to strengthen and build resilience in the supply chain for blood manufacturing.  
There will be three sessions focused on: (1) current challenges to supply chain disruptions involving blood manufacturing, (2) manufacturers’ perspectives on the root causes of supply chain disruptions and potential solutions, and (3) the role of federal agencies in strengthening and building resilience in the supply chain. For each session, there will be presentations from designated speakers, followed by a brief facilitated discussion. There will be an opportunity for public participation during an open public comment session.

Meeting Objectives:

• Describe the supply chain for blood manufacturing and identify what supplies and equipment are essential to manufacturing blood and blood components.
• Discuss current challenges and how blood collectors respond to shortages in the supply chain.
• Identify the root cause of shortages in the supply chain and propose solutions to prevent such shortages.
• Discuss the role of various federal agencies in strengthening the supply chain for blood manufacturing.

Final Agenda

9:00 – 9:15 a.m.	Welcome and Roundtable Objectives Anne Eder, MD, PhD Director, Office of Blood Research and Review (OBRR) CBER, FDA
9:15 - 10:45 a.m.	Session I:  Current State Moderator: Leah Mendelsohn Stone, JD Vice President (VP), Public Policy and Advocacy,  Association for the Advancement of Blood and Biotherapies (AABB) Panelists (15’ each): John Hagins Chair, AABB Interorganizational Task Force on Domestic Disasters     and Acts of Terrorism President and CEO, The Community Blood Center Bill Block President/CEO, Blood Centers of America James Knowles, PhD VP, Global and Regulatory Policy and Scientific Affairs, Plasma Protein Therapeutics Association (PPTA) Orieji Illoh, MD Deputy Director, OBRR, CBER, FDA Moderated Discussion (30’)
10:45 – 11:00 a.m.	Break (15’)
11:00 a.m. – 1:00 p.m.	Session II: Supply Chain Manufacturers Moderator: Mary Homer, PhD Program Director, CBRN Radiological and Nuclear Medical Countermeasures Program, BARDA (Biomedical Advanced Research and Development Authority), Administration for Strategic Preparedness and Response (ASPR) Panelists (15’ each): Janet Johnson VP, Global Regulatory, Clinical Affairs and Labeling, Terumo BCT Laurent Blime  Head of Supply Chain Management, MedTech Fresenius Kabi Global TechOps MedTech Helmut Hanske Director, Technical Marketing Haemonetics Corporation and Julie Ryan VP, Global Quality Assurance and Regulatory Affairs Haemonetics Corporation Alexandre Mouroz BPS Supply Chain Manager, Macopharma Richeal M. Cline Head of Diagnostics Global Operations, Roche Diagnostics Jon Arriaga Anchia VP, Diagnostic Industrial, Grifols Diagnostic Solutions Moderated Discussion (30’)
1:00 – 1:30 p.m.	Break (30’)
1:30 – 3:00 p.m.	Session III: Department of Health and Human Services Moderator: CAPT. John Oguntomilade, BDS, MPH, PhD Senior Advisor, HHS, Office of the Assistant Secretary for Health, Office of Infectious Disease and HIV/AIDS Policy Panelists (15’ each): Brooke Courtney, JD, MPH Senior Regulatory Counsel Office of Public Health Preparedness and Response Office of the Chief Medical Officer, Office of the Commissioner, FDA Tammy Beckham, DVM, PhD Director, Office of Supply Chain Resilience (OSCR) Office of Strategic Partnerships and Technology Innovation (OST) Center for Devices and Radiological Health (CDRH), FDA Mary Homer, PhD Program Director, CBRN Radiological and Nuclear Medical Countermeasures Program, BARDA, ASPR W. Wayland Coker, CSCP Acting Deputy Director, Center for Industrial Base Management and Supply Chain (IBMSC) Director, Office of Supply Chain Optimization (SCO) IBMSC, ASPR Moderated Discussion: (30’)
3:00 – 3:45 p.m.	Open Public Comments
3:45 – 4:00 p.m.	Concluding Remarks and Next Steps Anne Eder, MD, PhD Director, OBRR, CBER, FDA

Meeting Logistics and Registration:

The virtual meeting is free and open to the public; however, registration is required.  Early registration is recommended.

• Registration: To register for the webinar, please visit the following link: https://events.gcc.teams.microsoft.com/event/OBRRroundtable2026
• The registration for participation in the open public comment session has closed.
• Those who have requested to participate in the open public comment session will receive confirmation of participation by September 15, 2026.
• A recording and other relevant meeting materials will be posted online following the event.
• For questions regarding this event, please contact CBERPublicEvents@fda.hhs.gov.